Opportunity Information: Apply for PAR 25 170
The National Institutes of Health (NIH) is offering a cooperative agreement funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)" under Funding Opportunity Number PAR-25-170. The goal is to speed up the development and validation of biomarkers or clinical outcome assessments that are derived from digital health technologies (DHTs), such as wearable sensors, smartphone-based measures, or other remote data-capture tools, so they can be credibly used in clinical trials. A central emphasis is on creating measures that work for remote monitoring and that can serve as primary or secondary clinical trial endpoints, which means the outputs should be reliable and meaningful enough to support decision-making in studies that evaluate treatments or interventions.
A key requirement is that applicants must develop and test these digitally derived assessments across at least three different diseases or conditions. This multi-condition expectation is meant to increase real-world clinical impact, improve statistical feasibility (by demonstrating performance across varied populations and contexts), and promote standardization so that the same or closely comparable digital measures can be used more broadly rather than being narrowly tailored to a single disorder. In practice, the NIH is signaling that it wants tools that can generalize, with clear evidence that the measurement approach is robust across different clinical scenarios, rather than a one-off digital metric that only works in one setting.
The award mechanism is the phased UG3/UH3 cooperative agreement approach. Typically, this structure supports an initial milestone-driven phase (UG3) focused on planning, proof-of-concept work, and early validation steps, followed by a second phase (UH3) that expands to more rigorous testing and implementation once predefined milestones are met. Because it is a cooperative agreement rather than a standard grant, awardees should expect substantial NIH involvement in project oversight, including collaborative guidance, milestone tracking, and coordination around deliverables that support broader adoption and standardization. The announcement is labeled "Clinical Trial Optional," meaning applicants may propose a clinical trial if it is appropriate to their aims, but it is not mandatory for every application.
Partnerships with non-profit patient advocacy organizations are required. This reflects a strong expectation that measure development is grounded in patient priorities and real-world usability, and that patient communities help shape what outcomes matter, how burdensome data collection is, and how acceptable remote monitoring approaches are in everyday life. These partnerships also typically strengthen recruitment and retention strategies, improve cultural and contextual fit of digital tools, and help ensure that resulting endpoints are meaningful to patients and caregivers, not just technically measurable.
Eligibility is broad and spans many organization types, including state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); small businesses; and other entities. The announcement also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions.
At the same time, there are clear restrictions related to foreign involvement. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply under this opportunity. In other words, the applicant organization must be U.S.-based, and the funded components of the work must be conducted within eligible U.S. organizational structures rather than through non-U.S. branches or foreign organizational applicants.
This opportunity is categorized as discretionary funding and uses the cooperative agreement instrument type, with activity areas listed under education and health. It references CFDA numbers 93.399 and 93.853. The opportunity was created on 2024-11-13, and the original closing date listed is 2026-06-22. While an award ceiling and expected number of awards are not specified in the provided source information, the structure and requirements make it clear that NIH is looking for ambitious, cross-condition, patient-centered programs that produce standardized, clinically credible digital endpoints suitable for remote monitoring in clinical trials.Apply for PAR 25 170
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399, 93.853.
- This funding opportunity was created on 2024-11-13.
- Applicants must submit their applications by 2026-06-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is this NIH funding opportunity?
This is an NIH cooperative agreement funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)" under Funding Opportunity Number PAR-25-170.
2) What is the main goal of PAR-25-170?
The goal is to speed up the development and validation of biomarkers or clinical outcome assessments derived from digital health technologies (DHTs) so they can be credibly used in clinical trials. A central emphasis is on measures designed for remote monitoring and intended to be suitable as primary or secondary clinical trial endpoints.
3) What types of technologies count as digital health technologies (DHTs) for this opportunity?
Examples mentioned include wearable sensors, smartphone-based measures, and other remote data-capture tools. The focus is on digitally derived measures that support remote monitoring.
4) What does it mean that the outputs should be usable as clinical trial endpoints?
It means the digitally derived biomarker(s) or outcome assessment(s) should be reliable and meaningful enough to support decision-making in studies that evaluate treatments or interventions, including use as primary or secondary endpoints.
5) Is remote monitoring required, or just encouraged?
Remote monitoring is a central emphasis of this opportunity. The program is geared toward measures that work for remote monitoring and can be used in clinical trials as endpoints.
6) What is the requirement related to diseases or conditions?
Applicants must develop and test the digitally derived assessments across at least three different diseases or conditions.
7) Why does NIH require testing across at least three diseases or conditions?
The stated intent is to increase real-world clinical impact, improve statistical feasibility by demonstrating performance across varied populations and contexts, and promote standardization so comparable digital measures can be used broadly rather than being narrowly tailored to a single disorder.
8) Does NIH want a measure that works across multiple clinical scenarios?
Yes. NIH signals a preference for tools that generalize across different clinical scenarios, with clear evidence that the measurement approach is robust across conditions, rather than a one-off metric that only works in one setting.
9) What funding mechanism is being used?
The opportunity uses a phased UG3/UH3 cooperative agreement mechanism.
10) What is the UG3 phase intended to support?
The UG3 phase is typically a milestone-driven initial phase focused on planning, proof-of-concept work, and early validation steps.
11) What is the UH3 phase intended to support?
The UH3 phase typically expands to more rigorous testing and implementation after predefined milestones are met.
12) What does "cooperative agreement" imply for NIH involvement?
Because this is a cooperative agreement rather than a standard grant, awardees should expect substantial NIH involvement in oversight, including collaborative guidance, milestone tracking, and coordination around deliverables that support broader adoption and standardization.
13) Is a clinical trial required under this opportunity?
No. The announcement is labeled "Clinical Trial Optional," meaning applicants may propose a clinical trial if appropriate to their aims, but a clinical trial is not mandatory for every application.
14) Are partnerships required, and if so, with whom?
Yes. Partnerships with non-profit patient advocacy organizations are required.
15) Why are patient advocacy partnerships required?
The requirement reflects an expectation that measure development is grounded in patient priorities and real-world usability. Patient communities are expected to help shape what outcomes matter, how burdensome data collection is, and how acceptable remote monitoring approaches are in everyday life.
16) What practical benefits can patient advocacy partnerships provide (as described in the opportunity summary)?
The summary indicates these partnerships can strengthen recruitment and retention strategies, improve cultural and contextual fit of digital tools, and help ensure endpoints are meaningful to patients and caregivers, not just technically measurable.
17) Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organization types, including: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); small businesses; and other entities.
18) Are specific institution categories explicitly highlighted as eligible?
Yes. The opportunity highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; regional organizations; eligible federal agencies; Indian/Native American tribal governments that are not federally recognized; and U.S. territories or possessions.
19) Are foreign organizations eligible to apply?
No. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply.
20) Can a U.S. organization include a non-U.S. component in the proposed work?
No. Non-domestic components of U.S. organizations are also not eligible to apply under this opportunity.
21) What does the restriction on non-domestic components mean in practice?
Based on the summary, it means the applicant organization must be U.S.-based and the funded components of the work must be conducted within eligible U.S. organizational structures rather than through non-U.S. branches or foreign organizational applicants.
22) What type of funding category is this opportunity?
This opportunity is categorized as discretionary funding.
23) What instrument type is used for awards?
The instrument type is a cooperative agreement.
24) What activity areas are associated with this opportunity?
The listed activity areas are education and health.
25) What CFDA numbers are referenced?
The opportunity references CFDA numbers 93.399 and 93.853.
26) What are the key dates provided?
The opportunity was created on 2024-11-13, and the original closing date listed is 2026-06-22.
27) Is an award ceiling provided in the summary?
No. An award ceiling is not specified in the provided information.
28) Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided information.
29) What kind of projects does NIH appear to be looking for?
Based on the summary, NIH is looking for ambitious, cross-condition, patient-centered programs that produce standardized, clinically credible digital endpoints suitable for remote monitoring and use in clinical trials.
Browse more opportunities from the same category: Education, Health
Next opportunity: Enhancing Timely Data Reporting, Quality, and Use in Early Hearing Detection and Intervention (EHDI) Surveillance
Previous opportunity: Cooperative Agreement for CESU-affiliated Partner with Great Rivers Cooperative Ecosystem Studies Unit
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 170
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 170) also looked into and applied for these:
| Funding Opportunity |
|---|
| Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) Apply for PAR 25 241 Funding Number: PAR 25 241 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional) Apply for PAR 25 240 Funding Number: PAR 25 240 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) Apply for PAR 25 255 Funding Number: PAR 25 255 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) Apply for PAR 25 256 Funding Number: PAR 25 256 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) Apply for PAR 25 072 Funding Number: PAR 25 072 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) Apply for PAR 25 094 Funding Number: PAR 25 094 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) Apply for PAR 24 316 Funding Number: PAR 24 316 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) Apply for PAR 25 204 Funding Number: PAR 25 204 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) Apply for PAR 25 152 Funding Number: PAR 25 152 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) Apply for PAR 25 244 Funding Number: PAR 25 244 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) Apply for PAR 25 243 Funding Number: PAR 25 243 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) Apply for PAR 25 229 Funding Number: PAR 25 229 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) Apply for PAR 25 228 Funding Number: PAR 25 228 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) Apply for PAR 25 096 Funding Number: PAR 25 096 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) Apply for PAR 25 095 Funding Number: PAR 25 095 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) Apply for PAR 25 124 Funding Number: PAR 25 124 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) Apply for PAR 25 070 Funding Number: PAR 25 070 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) Apply for PAR 25 069 Funding Number: PAR 25 069 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Genomic Medicine Research (R21 Clinical Trial Optional) Apply for RFA HG 25 003 Funding Number: RFA HG 25 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) Apply for PAR 25 275 Funding Number: PAR 25 275 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 170", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.